vs

Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and Resolute Holdings Management, Inc. (RHLD). Click either name above to swap in a different company.

Axsome Therapeutics, Inc. is the larger business by last-quarter revenue ($196.0M vs $117.7M, roughly 1.7× Resolute Holdings Management, Inc.). Resolute Holdings Management, Inc. runs the higher net margin — -1.5% vs -14.6%, a 13.1% gap on every dollar of revenue. Resolute Holdings Management, Inc. produced more free cash flow last quarter ($189.2M vs $-18.7M).

Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.

Resolute Mining Limited is an Australian mining corporation focused on mining operations in Africa. It is currently operating two gold mines: the Syama Gold Mine in Mali and the Mako Gold Mine in Senegal.

AXSM vs RHLD — Head-to-Head

Bigger by revenue
AXSM
AXSM
1.7× larger
AXSM
$196.0M
$117.7M
RHLD
Higher net margin
RHLD
RHLD
13.1% more per $
RHLD
-1.5%
-14.6%
AXSM
More free cash flow
RHLD
RHLD
$208.0M more FCF
RHLD
$189.2M
$-18.7M
AXSM

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
AXSM
AXSM
RHLD
RHLD
Revenue
$196.0M
$117.7M
Net Profit
$-28.6M
$-1.7M
Gross Margin
55.7%
Operating Margin
-13.8%
30.2%
Net Margin
-14.6%
-1.5%
Revenue YoY
65.0%
Net Profit YoY
61.9%
EPS (diluted)
$-0.55
$-0.20

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AXSM
AXSM
RHLD
RHLD
Q4 25
$196.0M
$117.7M
Q3 25
$171.0M
$120.9M
Q2 25
$150.0M
$119.6M
Q1 25
$121.5M
$103.9M
Q4 24
$118.8M
Q3 24
$104.8M
Q2 24
$87.2M
Q1 24
$75.0M
Net Profit
AXSM
AXSM
RHLD
RHLD
Q4 25
$-28.6M
$-1.7M
Q3 25
$-47.2M
$-231.0K
Q2 25
$-48.0M
$-611.0K
Q1 25
$-59.4M
$-3.4M
Q4 24
$-74.9M
Q3 24
$-64.6M
Q2 24
$-79.3M
Q1 24
$-68.4M
Gross Margin
AXSM
AXSM
RHLD
RHLD
Q4 25
55.7%
Q3 25
59.0%
Q2 25
57.5%
Q1 25
52.5%
Q4 24
Q3 24
Q2 24
Q1 24
Operating Margin
AXSM
AXSM
RHLD
RHLD
Q4 25
-13.8%
30.2%
Q3 25
-27.0%
34.3%
Q2 25
-24.5%
34.0%
Q1 25
-46.9%
24.7%
Q4 24
-61.1%
Q3 24
-59.8%
Q2 24
-89.5%
Q1 24
-89.7%
Net Margin
AXSM
AXSM
RHLD
RHLD
Q4 25
-14.6%
-1.5%
Q3 25
-27.6%
-0.2%
Q2 25
-32.0%
-0.5%
Q1 25
-48.9%
-3.2%
Q4 24
-63.1%
Q3 24
-61.7%
Q2 24
-91.0%
Q1 24
-91.1%
EPS (diluted)
AXSM
AXSM
RHLD
RHLD
Q4 25
$-0.55
$-0.20
Q3 25
$-0.94
$-0.03
Q2 25
$-0.97
$-0.07
Q1 25
$-1.22
$-0.39
Q4 24
$-1.54
Q3 24
$-1.34
Q2 24
$-1.67
Q1 24
$-1.44

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AXSM
AXSM
RHLD
RHLD
Cash + ST InvestmentsLiquidity on hand
$322.9M
$205.5M
Total DebtLower is stronger
$169.8M
Stockholders' EquityBook value
$88.3M
$6.5M
Total Assets
$689.8M
$333.4M
Debt / EquityLower = less leverage
26.03×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AXSM
AXSM
RHLD
RHLD
Q4 25
$322.9M
$205.5M
Q3 25
$325.3M
$148.0M
Q2 25
$303.0M
$99.9M
Q1 25
$300.9M
$71.0M
Q4 24
$315.4M
Q3 24
$327.3M
Q2 24
$315.7M
Q1 24
$331.4M
Total Debt
AXSM
AXSM
RHLD
RHLD
Q4 25
$169.8M
Q3 25
$173.4M
Q2 25
$177.1M
Q1 25
$180.7M
Q4 24
Q3 24
Q2 24
Q1 24
Stockholders' Equity
AXSM
AXSM
RHLD
RHLD
Q4 25
$88.3M
$6.5M
Q3 25
$73.7M
$10.8M
Q2 25
$73.1M
$9.6M
Q1 25
$53.2M
$8.9M
Q4 24
$57.0M
Q3 24
$92.9M
Q2 24
$102.9M
Q1 24
$144.0M
Total Assets
AXSM
AXSM
RHLD
RHLD
Q4 25
$689.8M
$333.4M
Q3 25
$669.3M
$293.2M
Q2 25
$639.8M
$253.3M
Q1 25
$596.7M
$214.3M
Q4 24
$568.5M
Q3 24
$561.5M
Q2 24
$548.2M
Q1 24
$545.7M
Debt / Equity
AXSM
AXSM
RHLD
RHLD
Q4 25
26.03×
Q3 25
16.01×
Q2 25
18.42×
Q1 25
20.38×
Q4 24
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AXSM
AXSM
RHLD
RHLD
Operating Cash FlowLast quarter
$-18.7M
$196.1M
Free Cash FlowOCF − Capex
$-18.7M
$189.2M
FCF MarginFCF / Revenue
-9.6%
160.8%
Capex IntensityCapex / Revenue
0.0%
5.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-93.9M
$313.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AXSM
AXSM
RHLD
RHLD
Q4 25
$-18.7M
$196.1M
Q3 25
$1.0M
$59.6M
Q2 25
$-32.4M
$48.9M
Q1 25
$-43.4M
$18.4M
Q4 24
$-26.2M
Q3 24
$-18.6M
Q2 24
$-30.1M
Q1 24
$-53.5M
Free Cash Flow
AXSM
AXSM
RHLD
RHLD
Q4 25
$-18.7M
$189.2M
Q3 25
$988.0K
$58.6M
Q2 25
$-32.4M
$47.5M
Q1 25
$-43.7M
$17.8M
Q4 24
$-26.2M
Q3 24
$-18.7M
Q2 24
$-30.2M
Q1 24
$-53.6M
FCF Margin
AXSM
AXSM
RHLD
RHLD
Q4 25
-9.6%
160.8%
Q3 25
0.6%
48.5%
Q2 25
-21.6%
39.7%
Q1 25
-36.0%
17.1%
Q4 24
-22.1%
Q3 24
-17.9%
Q2 24
-34.6%
Q1 24
-71.4%
Capex Intensity
AXSM
AXSM
RHLD
RHLD
Q4 25
0.0%
5.8%
Q3 25
0.0%
0.8%
Q2 25
0.0%
1.2%
Q1 25
0.3%
0.6%
Q4 24
0.0%
Q3 24
0.1%
Q2 24
0.1%
Q1 24
0.1%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons